Role of small intestinal cytochromes P450 in the bioavailability of oral nifedipine

Drug Metabolism and Disposition

Volumn 35, Issue 9, 2007, Pages 1617-1623

  Zhang, Qing Yu ^a   Kaminsky, Laurence S ^a   Dunbar, Deborah ^a   Zhang, Jin ^a   Ding, Xinxin ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; NIFEDIPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME SUBSTRATE; GENE DELETION; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE; WILD TYPE;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HALF-LIFE; INTESTINE, SMALL; MALE; MICE; MICE, INBRED C57BL; MICROSOMES; NADPH-FERRIHEMOPROTEIN REDUCTASE; NIFEDIPINE;

MUS;

EID: 34548092793     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016543     Document Type: Article

References (40)

1. Bailey DG, Malcolm J, Arnold O, and Spence JD (1998) Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101-110.
2. Bailey DG, Spence JD, Munoz C, and Arnold JM (1991) Interaction of citrus juices with felodipine and nifedipine. Lancet 337:268-269.
3. Black SD and Coon MJ (1987) P-450 cytochromes: structure and function. Adv Enzymol Relat Areas Mol Biol 60:35-87.
4. Clarke L and Waxman DJ (1989) Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 49:2344-2350.
5. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173.
6. DohertyMMand Charman WN (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 41:235-253.
7. Echizen H and Eichelbaum M (1986) Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 11:425-449.
8. Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, and Watkins P (1999) 6′,7′- Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 65:237-244.
9. Fasco MJ, Silkworth JB, Dunbar DA, and Kaminsky LS (1993) Rat small intestinal cytochromes P450 probed by warfarin metabolism. Mol Pharmacol 43:226-233.
10. Grundy JS, Eliot LA, and Foster RT (1997) Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharm Drug Dispos 18:509-522.
11. Grundy JS, Eliot LA, Kulmatycki KM, and Foster RT (1998) Grapefruit juice and orange juice effects on the bioavailability of nifedipine in the rat. Biopharm Drug Dispos 19:175-183.
12. Gu J, Chen CS, Wei Y, Fang C, Xie F, Kannan K, Yang W, Waxman DJ, and Ding X (2007) A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition. J Pharmacol Exp Ther 321:9-17.
13. Gu J, Cui H, Behr M, Zhang L, Zhang Q-Y, Yang W, Hinson JA, and Ding X (2005) In vivo mechanisms of tissue-selective drug toxicity: effects of liver-specific knockout of the NADPH-cytochrome P450 reductase gene on acetaminophen toxicity in kidney, lung, and nasal mucosa. Mol Pharmacol 67:623-630.
14. Gu J, Weng Y, Zhang Q-Y, Cui HD, Behr M, Wu L, Yang WZ, Zhang L, and Ding X (2003) Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 278:25895-25901.
15. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
16. Henderson CJ, Otto DME, Carrie D, Magnuson MA, McLaren AW, Rosewell I, and Wolf CR (2003) Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 278:13480-13486.
17. Henderson CJ, Pass GJ, and Wolf CR (2006) The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicol Lett 162:111-117.
18. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, and Heidemann H (1996) The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121-1123.
19. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, and Sawada Y (2004) Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 143:856-864.
20. Iwao T, Inoue K, Hayashi Y, Yuasa H, and Watanabe J (2002) Metabolic extraction of nifedipine during absorption from the rat small intestine. Drug Metab Pharmacokinet 17:546-553.
21. Jankowski A and Lamparczyk H (1994) Evaluation of chromatographic methods for the determination of nifedipine in human serum. J Chromatogr A 668:469-473.
22. Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, and Piquette-Miller M (2004) Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos 32:20-27.
23. Kaminsky LS and Fasco MJ (1991) Small intestinal cytochromes P450. Crit Rev Toxicol 21:407-422.
24. Kaminsky LS and Zhang Q-Y (2003) The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 31:1520-1525.
25. Katoh M, Nakajima M, Yamazaki H, and Yokoi T (2001) Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 12:505-513.
26. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmacol Res 16:408-414.
27. Mohri K, Uesawa Y, and Sagawa K (2000) Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. Drug Metab Dispos 28:482-486.
28. Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Wain HM, and Nebert DW (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18.
29. Odou P, Ferrari N, Barthelemy C, Brique S, Lhermitte M, Vincent A, Libersa C, and Robert H (2005) Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. J Clin Pharmacol Ther 30:153-158.
30. Pass GJ, Carrie D, Boylan M, Lorimore S, Wright E, Houston B, Henderson CJ, and Wolf CR (2005) Role of hepatic cytochrome P450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome P450 reductase null mouse. Cancer Res 65:4211-4217.
31. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
32. Strobel HW, Hodgson AV, and Shen S (1995) NADPH cytochrome P450 reductase and its structural and functional domains, in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano PR, ed) pp 225-244, Plenum Publishing Corp., New York.
33. Suzuki H and Sugiyama Y (2000) Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12:3-12.
34. Weng Y, DiRusso CC, Reilly AA, Black PN, and Ding X (2005) Hepatic gene expression changes in mouse models with liver-specific deletion or global suppression of the NADPH-cytochrome P450 reductase gene. mechanistic implications for the regulation of microsomal cytochrome P450 and the fatty liver phenotype. J Biol Chem 280:31686-31698.
35. Wu L, Gu J, Cui H, Zhang Q-Y, Behr M, Fang C, Weng Y, Kluetzman K, Swiatek PJ, Yang W, et al. (2005) Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 312:35-43.
36. Wu L, Gu J, Weng Y, Kluetzman K, Swiatek P, Behr M, Zhang Q-Y, Zhuo X, Xie Q, and Ding X (2003) Conditional knockout of the mouse NADPH-cytochrome P450 reductase gene. Genesis 36:177-181.
37. Xu DX, Wang JP, Sun MF, Chen YH, and Wei W (2006) Lipopolysaccharide downregulates the expressions of intestinal pregnane X receptor and cytochrome P450 3a11. Eur J Pharmacol 536:162-170.
38. Yoshisue K, Nagayama S, Shindo T, and Kawaguchi Y (2001) Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. J Pharmacol Exp Ther 297:1166-1175.
39. Zhang Q-Y, Dunbar D, and Kaminsky LS (2003) Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos 31:1346-1351.
40. Zhang Q-Y, Wikoff J, Dunbar D, and Kaminsky L (1996) Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug Metab Dispos 24:322-328.